CytomX Therapeutics Inc (NAS:CTMX)
$ 1.2 0 (0%) Market Cap: 93.74 Mil Enterprise Value: -31.70 Mil PE Ratio: 8.57 PB Ratio: 0 GF Score: 55/100

CytomX Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 04:40PM GMT
Release Date Price: $7.85 (+2.21%)
Michael Klem

Good morning, and good afternoon, everybody. Thank you all for joining. My name is Michael Klem. I'm a member of JPMorgan's health care investment banking team here. It's my pleasure to introduce Sean McCarthy, the CEO of CytomX Therapeutics. (Operator Instructions) We also have Amy and Carlos here for Q&A after.

But without further ado, I'll turn it over to you, Sean. Thanks.

Sean A. McCarthy
CytomX Therapeutics, Inc. - Chairman, CEO & President

Great. Thank you very much, Michael, and it's a pleasure to be here today. Thanks to the organizers for the opportunity to present an update on our company. It's a real pleasure to provide an overview of our recent progress on our conditionally activated antibody therapeutic programs for the treatment of cancer and our plans for 2021 and beyond.

If we could advance -- if I could draw your attention to Slide 3. Before I begin, let me remind you that I will be making certain forward-looking statements during this presentation. Please refer to our regulatory filings with the SEC that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot